BridgeBio raises up to $1.2B, a month after submitting cardio drug to FDA

BridgeBio has tapped investors for up to $1.25 billion as it prepares to commercialize its heart pill and get some breathing room to continue running multiple clinical trials across cardiorenal, oncology and other disease areas.

The financing haul arrives a month after BridgeBio submitted acoramidis for FDA…
Click here to view original post